Ocean Biomedical, Inc. (OCEA)

1.7400 -0.0100 (-0.57%) At close: 04:00PM EDT

Ocean Biomedical, Inc.

Room 325, 55 Claverick Street
Providence, RI 02903
United States
401 444 7375
https://www.oceanbiomedical.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Elizabeth Ng M.B.A.	CEO & Director	N/A	N/A	1957
Dr. Inderjote Kathuria M.B.A., M.D.	Chief Strategy Officer	N/A	N/A	1967
Dr. Chirinjeev Baboo Kathuria M.B.A., M.D.	Founder & Executive Chairman of the Board	N/A	N/A	1965
Dr. Jack A. Elias M.D.	Founder, Chairman of Scientific Advisory Board & Independent Director	N/A	N/A	1951
Dr. Jonathan Kurtis M.D., Ph.D.	Founder, Chairman of Scientific Advisory Board & Director	N/A	N/A	1969
Ms. Jolie G. Kahn CPA, Esq.	Chief Financial Officer	N/A	N/A	1965
Mr. Robert John Sweeney	Chief Accounting Officer & Assistant Secretary	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

Corporate governance

Ocean Biomedical, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.